PFE | Weekly | Haru Insights

The FDA approval of IBRANCE as a maintenance therapy for HR+, HER2+ metastatic breast cancer marks a pivotal regulatory milestone, expanding its commercial potential and reinforcing Pfizer’s oncology pipeline credibility.
The Phase 3 trial failure of Ionis Pharmaceuticals’ Wainua (eplontersen) for ATTR-CM directly strengthens Pfizer’s competitive position in the ATTR-CM market, eliminating a major late-stage rival and bolstering Vyndaqel’s long-term franchise resilience.

Vyndaqel’s dominance in ATTR-CM is now unchallenged, with Ionis’ setback removing a key rival—this cements Pfizer’s grip on a high-margin rare disease market and ensures sustained revenue visibility.
The FDA’s approval of the KEYTRUDA/Padcev combo validates Pfizer’s ADC platform and elevates Padcev to a cornerstone oncology asset, unlocking new growth legs in immuno-oncology.
Patent extension for Vyndamax through June 2031 eliminates a looming revenue cliff, securing long-term profitability and fortifying Pfizer’s defensive moat in a niche but lucrative therapeutic area.
Pfizer’s $7.2 billion cost-savings initiative, paired with strong pipeline momentum and a reliable dividend, demonstrates rare financial discipline—positioning the company as a resilient play in a volatile pharma landscape.
With Vyndaqel’s franchise health solidified and no near-term competition, Pfizer can now focus on maximizing uptake and long-term patient retention, turning a rare disease asset into a cash cow.

Pfizer Inc. (PFE)[Tv]